Soltamox Tamoxifen Online Information

RSS Feed Homepage

Soltamox Tamoxifen Side Effects
2007-09-10 23:56:00
Adverse reactions to tamoxifen are relatively mild and rarely severe enough to require discontinuation of treatment in breast cancer patients. Continued clinical studies have resulted in further information which better indicates the incidence of adverse reactions with tamoxifen as compared to placebo. In one single-dose pharmacokinetic study in healthy perimenopausal and postmenopausal female volunteers, throat irritation was ...
More About: Side , Side Effects , Effects , Tamo

Order Tamoxifen | Dosage and Administration
2007-09-10 23:53:00
For patients with breast cancer, the recommended daily dose is 20-40 mg. Dosages greater than 20 mg per day should be given in divided doses (morning and evening). A 20 mg dose of SOLTAMOXÃ? is administered as 10 mL (equivalent to 2 teaspoons) of the oral solution. In three single agent adjuvant studies in women, one ...
More About: Administration , Order , Tamo , Stration

Reduction in Breast Cancer Incidence in High Risk Women with Soltamox Tamox
2007-09-10 23:48:00
Tamoxifen citrate is indicated to reduce the incidence of breast cancer in women at high risk for breast cancer. This effect was shown in a study of 5 years planned duration with a median follow-up of 4.2 years. Twenty-five percent of the participants received drug for 5 years. The longer term effects are not known. ...
More About: Women , Cancer , Breast Cancer , Breast , Risk

Ductal Carcinoma in Situ (DCIS)
2007-09-10 23:46:00
In women with DCIS, following breast surgery and radiation, tamoxifen citrate is indicated to reduce the risk of invasive breast cancer. The decision regarding therapy with tamoxifen for the reduction in breast cancer incidence should be based upon an individual assessment of the benefits and risks of tamoxifen therapy. Current data from clinical trials support five ...

Purchase Soltamox | Tamoxifen Indications
2007-09-10 23:44:00
Metastatic Breast Cancer Tamo xifen citrate is effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, tamoxifen citrate is an alternative to oophorectomy or ovarian irradiation. Available evidence indicates that patients whose tumors are estrogen receptor positive are more likely to benefit from tamoxifen citrate therapy. Adjuvant Treatment ...
More About: Purchase , Indica , Hase

Tamoxifen Reduction in Breast Cancer Incidence in High Risk Women
2007-09-10 23:39:00
The Breast Cancer Prevention Trial (BCPT, NSABP P-1) was a double-blind, randomized, placebo-controlled trial with a primary objective to determine whether 5 years of tamoxifen therapy (20 mg/day) would reduce the incidence of invasive breast cancer in women at high risk for the disease . Secondary objectives included an evaluation of the incidence of ischemic ...
More About: Women , Breast Cancer , Risk

Soltamox Tamoxifen Contralateral Breast Cancer
2007-09-10 23:37:00
The incidence of contralateral breast cancer is reduced in breast cancer patients (premenopausal and postmenopausal) receiving tamoxifen compared to placebo. Data on contralateral breast cancer are available from 32,422 out of 36,689 patients in the 1995 overview analysis of the Early Brea st Cancer Trialists Collaborative Group (EBCTCG). In clinical trials with tamoxifen of 1 year ...
More About: Breast Cancer , Tamo

Tamoxifen Therapy Duration
2007-09-10 23:35:00
In the EBCTCG 1995 overview, the reduction in recurrence and mortality was greater in those studies that used tamoxifen for about 5 years than in those that used tamoxifen for a shorter period of therapy. In the NSABP B-14 trial, in which patients were randomized to tamoxifen 20 mg/day for 5 years vs. placebo and were ...
More About: Therapy , Erap , Tamo , Thera

Tamoxifen Breast Cancer Prevention | Individual Studies
2007-09-10 23:33:00
NSABP B-14, a prospective, double-blind, randomized study, compared tamoxifen to placebo in women with axillary node-negative, estrogen-receptor positive (=10 fmol/mg cytosol protein) breast cancer (as adjuvant therapy, following total mastectomy and axillary dissection, or segmental resection, axillary dissection, and breast radiation). After five years of treatment, there was a significant improvement in disease-free survival in ...
More About: Studies , Cancer , Prevention , Breast Cancer , Breast

Tamoxifen Citrate Research | Individual Studies
2007-09-10 23:31:00
Two studies (Hubay and NSABP B-09) demonstrated an improved disease-free survival following radical or modified radical mastectomy in postmenopausal women or women 50 years of age or older with surgically curable breast cancer with positive axillary nodes when tamoxifen was added to adjuvant cytotoxic chemotherapy. In the Hubay study, tamoxifen was added to “low-dose” CMF ...
More About: Studies , Research , Individual , Rate , Citrate